目的 探讨康艾注射液联合mFOLFOX6方案治疗晚期胃癌的临床疗效。方法 选取2022年4月—2024年3月在新疆医科大学第一附属医院诊断为晚期胃癌且拒绝手术切除或无手术切除指征的82例患者，按随机数字表法将患者分为对照组和治疗组，每组41例。对照组给予mFOLFOX6方案，药物包括奥沙利铂注射液、注射用左亚叶酸钙、氟尿嘧啶注射液。治疗组在对照组基础上静脉滴注康艾注射液，60 mL加入250 mL生理盐水后静脉滴注，1次/d，持续治疗2周，停药1周。3周为1个治疗周期，两组在治疗3个治疗周期后分析疗效。比较两组治疗效果、生活质量、血清肿瘤标志物、免疫指标和不良反应。结果 治疗组的疾病控制率明显高于对照组，组间差异显著（95.12% vs 80.49%，P＜0.05）。治疗后，两组的KPS评分高于治疗前（P＜0.05），且治疗组的KPS评分较对照组更高（P＜0.05）。治疗后，两组的血清组织多肽特异性抗原（TPS）、癌胚抗原（CEA）、糖类抗原724（CA724）水平低于治疗前（P＜0.05）；治疗组的血清TPS、CEA、CA724水平均比对照组低（P＜0.05）。治疗后，两组的PLR、NLR小于治疗前（P＜0.05）；治疗组的PLR、NLR小于对照组（P＜0.05）。治疗组的口腔炎症、恶心呕吐、白细胞减少例数低于对照组（P＜0.05）。结论 康艾注射液联合mFOLFOX6方案可提高晚期胃癌的疾病控制率，改善患者生活质量，降低肿瘤标志物水平，减轻炎症反应，降低不良反应的发生。

Objective To investigate the clinical efficacy of Kangai Injection combined with mFOLFOX6 regimen in treatment of advanced gastric cancer. Methods 82 Patients with advanced gastric cancer who refused surgical resection or had no indications for surgical resection at The First Affiliated Hospital of Xinjiang Medical University from April 2022 to March 2024 were divided into control group and treatment group using a random number table method, with 41 patients in each group. The control group was treated with mFOLFOX6 regimen, which included Oxaliplatin Injection, Calcium Folinate for injection, and Fluorouracil Injection. Patients in treatment group were iv administered with Kangai Injection on the basis of the control group, with 60 mL added to 250 mL of physiological saline and intravenous infusion once daily. The treatment was continued for 2 weeks and stopped for 1 week. Three weeks was a course, and the clinical efficacies of the two groups were analyzed after three courses. The treatment efficacy, quality of life, serum tumor markers, immune indicators, and adverse reactions between two groups were compared. Results The disease control rate of the treatment group was significantly higher than that of the control group, with a significant difference between two groups (95.12% vs 80.49%, P < 0.05). The KPS scores of the two groups after treatment were higher than those before treatment (P < 0.05), and the KPS scores of the treatment group was higher than those in the control group (P < 0.05). The serum levels of TPS, CEA, and CA724 in both groups were lower than those before treatment (P < 0.05), and the serum levels of TPS, CEA, and CA724 levels in the treatment group were lower than those in the control group (P < 0.05). PLR and NLR of both groups after treatment were lower than those before treatment (P < 0.05), and the PLR and NLR of the treatment group were lower than those of the control group (P < 0.05). The oral inflammation, nausea and vomiting, and leukopenia in the treatment group were lower than those in the control group (P < 0.05). ConclusionThe combination of Kangai Injection and mFOLFOX6 regimen can improve the disease control rate of advanced gastric cancer, improve patients' quality of life, reduce tumor marker levels, alleviate inflammatory reactions, and reduce the occurrence of adverse reactions.

R979.1

新疆维吾尔自治区自然科学基金青年项目(2021D01C328)